National Institutes of Health.

To be very clear, Ascentage is used to benchmark the Chinese innovative drugs of Switzerland's Roche and Novartis. Ascentage is the lowest-valued and highest-quality super target in the global market, including the US stock market, Hong Kong, and mainland China.